Clinical trial
Addition of Quetiapine in Obsessive Compulsive Disorder - Westenberg Study
NCT00318539 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00318539 |
|---|---|
| Title | Addition of Quetiapine in Obsessive Compulsive Disorder - Westenberg Study |
| Official title | Quetiapine Augmentation to SRIs for Patients With Obsessive Compulsive Disorder, a Double-blind, Placebo-controlled Study |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Obsessive Compulsive Disorder |
| Intervention type | Drug |
| Interventions | Quetiapine |
| Enrollment | 90 |
| Start date | Dec 1, 2003 |
| Completion | Aug 1, 2006 |
| First posted | Apr 27, 2006 |
| Last update posted | Jan 21, 2011 |
| Countries | Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: